RxDoctor Payments DataLook up a doctor →

Sammi Smith, MD

Acute Care · Shreveport, LANPI 1013982693

Payments from drug & device makers

$9,599in general payments, 2019–2025

Across 529 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$804
  • Medtronic$720
  • Corcept Therapeutics$617
  • Dexcom, Inc.$549
  • Sanofi-aventis U.S. LLC$496
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$9,50899%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,599 in reported general payments places this provider in the 95th percentile of 248 acute care providers in Louisiana.

See all acute care providers in Louisiana

Medicare billing

Part B allowed, 2024
$64,518
Medicare patients
210
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide129$148,680
JardianceEmpagliflozin68$52,009
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/739$51,526
OzempicSemaglutide31$41,811
Tresiba Flextouch U-200Insulin Degludec35$40,200
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$33,581
FarxigaDapagliflozin Propanediol20$25,295
Tresiba Flextouch U-100Insulin Degludec46$25,118
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$23,978
TrulicityDulaglutide21$21,764
NovologInsulin Aspart49$21,733
Gvoke Hypopen 2-PackGlucagon27$15,957
HumalogInsulin Lispro39$8,906
SynthroidLevothyroxine Sodium110$6,148
Novolog FlexpenInsulin Aspart30$5,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$804$180,901208 claims
Novo NordiskOzempic, Novolog$1,252$63,54480 claims
Boehringer IngelheimJardiance$116$52,00968 claims
AstraZenecaFarxiga$96$25,29520 claims
AbbVieSynthroid, Armour Thyroid$466$9,725149 claims
Sanofi-aventis U.S. LLCLantus$496$2,36918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 acute care providers in Louisiana.

Other acute care in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →